Time filter

Source Type

News Article | May 14, 2017
Site: www.prnewswire.com

The Impact of Cycling on Men's Sexual and Urinary Functions (#PD45-05): Researchers conducted a survey of male athletes recruited from English-speaking sports clubs throughout the world. The study included nearly 4,000 participants, of whom 63 percent were cyclists who did not swim or run and 37 percent were swimmers or runners who did not cycle. Participants were queried about their physical activity and answered validated questionnaires including: The Sexual Health Inventory for Men (SHIM), International Prostate Symptom Score (I-PSS) and the National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI). High intensity cycling was defined as cycling for longer than two years, more than three times per week and a daily average of more than 25 miles. The Impact of Cycling on Women's Sexual and Urinary Functions (# PD44-03): Researchers also conducted an international study on female athletes recruited from English-speaking sports clubs to determine if cycling has an effect on the female genitourinary tract. The study included 2,691 participants. Thirty-nine percent (658) were cyclists and 61 percent (1,013) were swimmers or runners who did not regularly cycle. Participants answered questions about their physical activities, sexual function, urinary symptoms, history of urinary tract infections (UTI) and perineal numbness using the Female Sexual Function Inventory (FSFI) and the I-PSS. As cycling gains in popularity, as both a hobby and a professional sport, it is important for the public to know that it has no credible link to urologic disease or sexual dysfunction," says Dr. McVary. "Men and women can benefit from the cardiovascular exercise of cycling without worrying about negative side effects to their urinary tract or sexual performance." NOTE TO REPORTERS: Experts are available to discuss this study outside normal briefing times. To arrange an interview with an expert, please contact the AUA Communications Office at 410-689-3932 or e-mail cfrey@AUAnet.org. About the American Urological Association: The 112th Annual Meeting of the American Urological Association takes place May 12 – 16 at the Boston Convention & Exhibition Center in Boston, MA. Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has more than 21,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health policy. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/does-cycling-affect-mens-and-womens-sexual-health-and-urinary-functions-300456701.html


News Article | May 10, 2017
Site: www.techradar.com

To meet the surging demand for expertise in the field of artificial intelligence (AI), US-based manufacturer of graphics processor technologies NVIDIA on Tuesday announced it will train 100,000 developers this year via the NVIDIA Deep Learning Institute. The NVIDIA Deep Learning Institute provides developers, data scientists and researchers with practical training on the use of the latest AI tools and technology. "AI is the defining technology of our generation. To meet overwhelming demand from enterprises, government agencies and universities, we are dramatically expanding the breadth and depth of our offerings, so developers worldwide can learn how to leverage this transformative technology," said Greg Estes, Vice President of Developer Programmes at NVIDIA, in a statement. Analyst firm International Data Corporation (IDC) estimates that 80 percent of all applications will have an AI component by 2020. The NVIDIA institute has trained developers around the world at public events and onsite training at companies such as Adobe, Alibaba and SAP and at government research institutions like the US National Institute of Health, National Institute of Science and Technology and the Barcelona Supercomputing Centre. It has also trained developers at the institutes of higher learning such as Temasek Polytechnic Singapore and India Institute of Technology, Bombay. NVIDIA is broadening the Deep Learning Institute's curriculum to include the applied use of deep learning for self-driving cars, healthcare, web services, robotics, video analytics and financial services. "There is a real demand for developers who not only understand artificial intelligence, but know how to apply it in commercial applications," added Christian Plagemann, Vice President of Content at Udacity. NVIDIA is also working with Microsoft Azure, IBM Power and IBM Cloud teams to port lab content to their cloud solutions.


SYNOPSIS: In the early 90s, a mysterious muscular disease with symptoms that included severe muscle and joint pain began to surface among patients in France. Doctors in Paris discovered that these patients had developed a new disease called Macrophagic Myofascitis, or MMF, which occurs when the aluminum hydroxide adjuvant from a vaccine remains embedded in the muscle tissue. What the pharmaceutical companies don't reveal is that the aluminum adjuvant was never rigorously tested before going on the market and there are alternative, much less toxic, adjuvants available. Featuring interviews with patients, doctors, scientists, and influential politicians, Injecting Aluminum examines aluminum's devastating effects on the human body and calls into question the public health policies around aluminum in vaccines. Directed by Marie-Ange Poyet, Injecting Aluminum features groundbreaking interviews with leading aluminum specialists such as "Mr. Aluminum", Dr. Christopher Exley, PhD in the Ecotoxicology of Aluminum, Dr. Yehuda Shoenfeld, founder of the leading Centre for Autoimmune Diseases at the Sheba Medical Center, Dr. Romain Gherardi, the Director of the French National Institute of Health and Medical Research, and Dr. Jérôme Authier, neurologist and head of the Center of Reference of neuromuscular diseases of the Henri Mondor Hospital in Créteil, France. Injecting Aluminum has a running time of 90 minutes, and is not rated. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/toxic-impact-of-aluminum-in-vaccines-investigated-in-new-documentary-injecting-aluminum-300456303.html


News Article | May 9, 2017
Site: globenewswire.com

Support Potential of ADX71441 to treat Irritable Bowel  Syndrome, Interstitial Cystitis and Painful Bladder Syndrome Geneva, Switzerland, 9 May 2017 - Addex Therapeutics (SIX: ADXN) announced today positive results from multiple preclinical studies of ADX71441, a positive allosteric modulator (PAM) of the gamma-aminobutyric acid subtype B (GABAB) receptor, in models of visceral hyperalgesia. The studies were led by Prof. Jyoti N. Sengupta at the Medical College of Wisconsin, with the support of a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the US National Institute of Health. The findings strongly support the potential of ADX71441 in treating hyperalgesia in colonic inflammation (colitis) and bladder inflammation (cystitis). Chronic visceral pain syndromes related to the gastrointestinal or urinary tract represent an important unmet medical need as they can significantly impact the patient's quality of life. "These data represent an important step forward in the understanding of the role played by GABAB receptors in visceral pain and the potential of ADX71441 in large unmet medical needs, such as irritable bowel syndrome, interstitial cystitis and painful bladder syndrome," said Sonia Poli, CSO of Addex. "We look forward to continuing our collaboration with Prof Sengupta's group, and further evaluating the possibility of conducting clinical trials for ADX71441 in these compelling indications." The effect of ADX71441 was studied in reliable, reproducible and quantifiable preclinical models of visceral pain, which included behavioral measurements and electrophysiology recordings(1). Visceral motor reflex after colorectal distension (CRD) and urinary bladder distension (UBD) was significantly decreased (p<0.05) following systemic administration of ADX71441 (5, 10 and 50 mg/kg ip). The visceral analgesic effect of ADX71441 did not affect the normal function of the bladder as assessed by cystometry. In electrophysiology experiments, ADX71441 demonstrated significant inhibition of the response of UBD responsive lumbo-sacral (LS) spinal dorsal horn neurons to graded bladder distension. The effect was observed in spinal intact rats, but not in cervical (C1-C2) spinal transected rats. It also produced a moderate decrease in the spontaneous firing of these neurons in spinal intact rats. ADX71441 had no effect on the mechano-transduction properties or the spontaneous firing of UBD-sensitive pelvic nerve afferent (PNA) fibers. The current behavioral experiments to assess pain and the electrophysiology results indicate that ADX71441 produces visceral analgesia in animal models of cystitis and colitis.  The results indicate that ADX71441 produces this analgesic effect primarily by acting at the supra-spinal sites without affecting bladder motility. "We thank the NIDDK for their support and Prof. Sengupta and his team for their dedication to this important research with ADX71441," commented Tim Dyer, CEO of Addex. "These compelling results are a further example of how we are leveraging our collaborations with leading academic institutions to better understand the potential of the promising candidates in our pipeline." About GABA B receptor The GABAB receptor is clinically & commercially validated. Generic GABAB receptor agonist, baclofen, is marketed for spasticity and some spinal cord injuries, and French health authorities have approved its use for the treatment of alcoholism. Baclofen is also used off label for a number of other indications including overactive bladder (OAB), but its utility is limited due to variety of side effects and rapid clearance, requiring frequent administration of higher doses. About ADX71441 ADX71441 is a potent selective positive allosteric modulator (PAM) which potentiates GABA responses at the GABAB receptor. ADX71441 is a novel, first-in-class, oral, small molecule that demonstrated excellent preclinical efficacy and tolerability in rodent models of pain, anxiety, OAB, alcohol use disorders, nicotine dependence and in a non-human primate model of cocaine use disorder. ADX71441 has also proven efficacy in a genetic model of Charcot-Marie-Tooth Type 1A disease (CMT1A). ADX71441 has a different molecular mechanism from the generic drug baclofen in that it is a positive allosteric modulator, rather than an orthosteric agonist at the GABAB receptor, with a longer half-life, suitable for once daily administration. ADX71441 only acts when the natural ligand (GABA) activates the receptor, therefore respecting the physiological cycle of activation. It has been proposed that PAMs produce less adverse effects and lead to less tolerance than direct agonists. Addex Therapeutics (www.addextherapeutics.com) is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention - the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform. Addex's lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a Phase 2a POC in Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID with support from the Michael J. Fox Foundation for Parkinson's Research (MJFF). In parallel, dipraglurant's therapeutic use in dystonia is being investigated with support from the Dystonia Medical Research Foundation (DMRF). Addex's second clinical program, ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc for epilepsy. In addition, ADX71441 (GABAB receptor PAM) has received regulatory approval to start Phase 1 and is being investigated for its therapeutic use in Charcot-Marie-Tooth Type 1A disease (CMT1A), cocaine and alcohol use disorder and nicotine dependence. Discovery programs include mGluR4PAM, mGluR7NAM, TrkBPAM and mGluR3NAM & PAM. Disclaimer / Forward-looking statements: This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Addex Therapeutics Ltd. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.


With an upcoming publication in the Worldwide Leaders in Healthcare, Dr. Angelia Cleark McDowell, DNP, MSN, BSN, APRN, PMHNP-BC, joins the prestigious ranks of the International Nurses Association. Angelia Cleark McDowell is a Nurse Practitioner with seven years of experience in her field and extensive expertise in all facets of nursing, especially mental health, inpatient rehabilitation, medical/surgical nursing, telemetry nursing, and corrections nursing. Angelia is currently serving as a psychiatric mental health nurse practitioner at an outpatient mental health facility in Southaven, Mississippi serving patients with an array of mental health care needs. Previously, Angelia worked with the Corrections Corporation of America  in Tutwiler, Mississippi as a staff nurse and staff RN on the inpatient rehabilitation unit at Northwest Mississippi Regional Medical Centers in Clarksdale, Mississippi. Angelia Cleark McDowell graduated with her Associate of Arts Degree in General Business in 2006 and her Associate Degree in Nursing in 2010 from Coahoma Community College in Clarksdale, Mississippi, where she received the Highest GPA Nursing Award. An advocate for continuing education, Angelia went on to receive her Bachelor of Science Degree in Nursing in 2012 from the University of Texas at Arlington, followed by her Master of Science Degree in Nursing with a Psychiatric Mental Health Nurse Practitioner specialty from the University of South Alabama in 2015. Angelia also received her Doctor of Nursing Practice Degree from University of South Alabama in 2016. Angelia is certified in EKG Interpretation and Tuberculosis Surveillance and Testing. Angelia also received a certification of completion from the United States Department of Health and Human Services, Health Resources and Services Administration for providing clinical care and services to underserved populations. She received certification from the National Institute of Health in 2013, as well as certification with the Collaborative Institutional Training Initiative in 2013. Angelia also holds certifications in Advanced Cardiovascular Life Support and Pediatric Advanced Life Support. To keep up to date with the latest advances and developments in her field, Angelia maintains a professional membership with the Mississippi Nurses Association, the National Scholars Honor Society, and the Sigma Theta Tau International Honor Society of Nursing. For her hard work and unwavering dedication, Angelia received an Award of Excellence for Mental Health Nursing, an Award of Excellence for Fundamentals of Nursing, and several Academic Excellence Awards for Academic Achievement by Coahoma Community College. She attributes her success to the support of her family, particularly her husband, who has been her greatest supporter and encourages her to supersede her own expectations. When she is not assisting her patients, Angelia enjoys reading, cooking, and physical fitness. Learn more about Dr. Angelia Cleark McDowell here: http://inanurse.org/network/index.php?do=/4122136/info/ and be sure to read her upcoming publication in the Worldwide Leaders in Healthcare.


News Article | May 24, 2017
Site: www.eurekalert.org

MADISON, Wisconsin - Mindfulness may be good for new moms. A study this month from researchers at the University of Wisconsin-Madison and the University of California, San Francisco (UCSF) shows mindfulness training that addresses fear and pain during childbirth can improve women's childbirth experiences and reduce their depression symptoms during pregnancy and the early postpartum period. "Fear of the unknown affects us all, and perhaps none more so than pregnant women," says lead author Larissa Duncan, UW-Madison professor of human development and family studies. "With mindfulness skills, women in our study reported feeling better able to cope with childbirth and they experienced improved mental well-being critical for healthy mother-infant adjustment in the first year of life." The study also suggests that pregnant women who practice mindfulness may use less medication for pain during labor. Many women and their healthcare providers are concerned about the use of medications during pregnancy, labor and while breastfeeding because of the potential risks to infants. Yet, left untreated, maternal mental health problems also pose a significant risk to infants. "A mindfulness approach offers the possibility of decreasing the need for these medications and can reach women who may not know they are at risk for perinatal depression or can't access mental health services," Duncan says. The new study, published in the journal BMC Pregnancy and Childbirth, is a randomized, controlled trial called Prenatal Education About Reducing Labor Stress (PEARLS), compares mainstream childbirth education with childbirth education that includes mindfulness skills focused on reducing fear among first-time mothers. Fear of childbirth has been shown in previous studies to be linked to poorer labor-and-delivery outcomes and to depression. While many consider childbirth education classes a primary resource for pregnant women and their partners to learn information and strategies for the birthing process and remedies for coping with labor pain, there is limited data that demonstrates they achieve these goals for the more than 2 million pregnant women who attend them each year in the United States. In fact, Duncan says, "sometimes women report that the information in childbirth education actually increases their fear of childbirth." For the study, considered a pilot because funding limited participation to 30 women and their partners, first-time mothers late in their third trimester of pregnancy were offered either a standard childbirth preparation course lacking a mind-body focus or an intensive weekend workshop called Mind in Labor: Working with Pain in Childbirth. The workshop was based on the Mindfulness-Based Childbirth and Parenting education course developed by study co-author, Nancy Bardacke, a certified nurse-midwife and senior mindfulness teacher at UCSF. It focused on practices like mindful movement, walking meditation, and pain coping strategies. Previous research shows that mindfulness training can be an effective way to manage both chronic and acute pain. Participants represented a diversity of ethnic and socioeconomic backgrounds. They completed self-reported assessments before and after taking part in a childbirth education course and after giving birth. The mindfulness group also received handouts and guided audio materials so they could practice mindfulness on their own. The study team collected medical record data from each woman. The researchers found a reduction in depression symptoms in the mindfulness group, which continued through their post-birth follow up at approximately six weeks. In contrast, depression symptoms worsened among women who participated in the standard childbirth education courses. While mothers in the mindfulness group sought epidurals at similar rates to those in the control group and retrospectively reported similar levels of perceived pain during labor, the study did see a trend toward lower use of opioid-based pain medication during labor. While these results were not statistically significant, the rate of narcotic use during labor was around 62 percent in the control group and just 31 percent in the mindfulness group. A larger study is needed to better understand this effect. "The encouraging results of this small study point to the possibility that mindfulness skills can transform the way expectant parents prepare for this profound life change," says Bardacke. "In addition to supporting moms and babies, we may also be benefiting fathers, who are themselves experiencing the birth of their child and becoming parents. While more research is clearly needed, the larger public health implications of this work are motivating." More information about the Mindfulness-Based Childbirth and Parenting program can be found at http://www. . The study was funded through a grant from the Mount Zion Health Fund administered by the University of California, San Francisco School of Medicine and U.S. National Institute of Health/National Center for Complementary and Integrative Health grants K01 AT005270 and K01 AT006545. Disclosure: Larissa Duncan holds an unpaid position as board member of the Mindful Birthing and Parenting Foundation. Nancy Bardacke receives royalties from the sale of a book related to the intervention tested in the study as well as related CD/mp3 audio materials and an app. Through the not-for-profit Mindful Birthing and Parenting Foundation, she also receives payments for professional trainings and mindfulness workshops for pregnant women and their partners.


Oakland, Kalifornien und BOSTON und KOPENHAGEN, Dänemark--(BUSINESS WIRE)--Fabric Genomics, ein weltweit tätiges Unternehmen für Computergenomik, das Tools für Datenanalysen und klinische Berichte anbietet, hat heute eine Partnerschaft mit dem Datenverwaltungsunternehmen ITTM S.A. (Information Technology for Translational Medicine, Informationstechnologie für die Translationsmedizin) bekanntgegeben. Gemeinsam will man sichere Möglichkeiten zum Webhosting von Genomdaten für Kunden in der EU anbieten. Durch die Verbindung der führenden Analysetools von Fabric Genomics mit den bewährten, sicheren Lösungen von ITTM für Hosting und Infrastruktur schaffen wir erstklassige Lösungen für Genomtechnologie und Datenschutz für Patienten in klinischen Labors, bei Pharmafirmen und Genomprojekten. Die Analysetools von Fabric Genomics werden bereits von Kunden in der EU genutzt. Das 100.000 Genomes Project von Genomics England etwa ist ein bahnbrechendes Projekt für landesweite Genomsequenzierung mit Schwerpunkt auf seltenen Erkrankungen und Krebs. Unsere klinische Plattform Opal hat mehr als 500 klinische Berichte für das 100.000 Genomes Project geliefert, mit dem Ziel der Verbesserung therapeutischer Behandlungen durch die Genommedizin. Fabric Genomics expandiert in der EU; die Erfolgsbilanz des Unternehmens umfasst hier Kunden wie LabCorp, eines der größten Referenzlabore in den USA, das Rady Children’s Institute for Genomic Medicine, das unter der Leitung von Dr. Stephan Kingsmore eines der herausragendsten klinischen Genomzentren für die Pädiatrie ist, sowie das Vanderbilt University Medical Center, ein klinischer Standort für das UDN (Undiagnosed Disease Network, Netzwerk für nicht diagnostizierte Krankheiten) des National Institute of Health. „Wir haben uns aufgrund der Expertise des Unternehmens mit schnellen und präzisen Genomanalysen für Fabric Genomics als einen unserer zentralen NGS-Partner für den EU-Markt entschieden”, sagte Andreas Kremer, Ph.D., Mitgründer und General Manager von ITTM. „NGS-Tests verbreiten sich in Europa zusehends, und es gibt einen Bedarf für die Interpretation von Genomdaten der Patienten in einem sicheren Umfeld. Immer mehr Kliniker sequenzieren Patientendaten für seltene Erkrankungen und Krebs, und es besteht Bedarf für schnelle und präzise Interpretationen dieser Daten. In einigen EU-Ländern verbieten Vorschriften den Transfer persönlicher Daten über Grenzen hinweg. Wir freuen uns also sehr, dass wir die optimalen Hosting-Dienste für diejenigen Kunden liefern können, die keine eigenen Server haben.” Fabric Genomics™ ist ein weltweit tätiges Unternehmen für Computergenomik, das Komplettlösungen für Analysen, Kommentare, Kuratierung, Klassifizierung und Berichte für Genomdaten für klinische Labore, Krankenhauslabore und landesweite Sequenzierungsprogramme sowie Unternehmen im Bereich der Biowissenschaften anbietet. Die Analysemöglichkeiten von Fabric Genomics beginnen mit der Analyse von Rohdaten und umfassen die Bereitstellung schneller, umfassender Einblicke für Panels mit hohem Datendurchsatz, Exome und ganze Genome. Unsere Software kann FASTQ-, BAM- oder VCF-Dateien verarbeiten und liefert Abstimmung, Variantenbestimmung, richtliniengestützte Variantenklassifizierung, Varianteninterpretation und klinische Berichte für Erbkrankheiten und Onkologie. Unsere bahnbrechende Biograph-Technologie ermöglicht die präzise Erkennung struktureller Varianten und bietet Möglichkeiten zum Daten-Mining im Maßstab ganzer Bevölkerungen. Fabric Genomics wurde von Wissenschaftlern und Branchenpionieren aus den Bereichen Bioinformatik, Genomik im großen Maßstab und Molekulardiagnostik gegründet und hat seinen Hauptsitz in Kalifornien. Durch die Beschleunigung des Zugangs zu Einblicken im Zusammenhang mit den Ursachen genetisch bedingter Erkrankungen steht Fabric Genomics in der Präzisions-Gesundheitsversorgung an der Spitze. Folgen Sie uns auf Twitter, LinkedIn und Facebook.


News Article | May 23, 2017
Site: www.prnewswire.com

"At StemGenex, we are committed to helping people achieve optimum health and better quality of life through the healing benefits of their own stem cells," said Alexander.  "Specifically, we use adipose-derived adult stem cell therapy for patients battling conditions such as Multiple Sclerosis, Parkinson's disease, COPD, Rheumatoid Arthritis and Osteoarthritis. We are also committed to the science of stem cell therapy and sponsor five clinical outcome studies registered with the National Institute of Health (NIH) for these diseases." "What I personally witnessed before the start of  StemGenex were patients who had exhausted conventional medical treatments but wanted to try alternative therapies. I was one of them, suffering from severe Rheumatoid Arthritis. I had only three options; I could seek a clinical trial, travel to outside of the U.S. to try alternative therapies such as stem cell treatment or petition the FDA for access to drugs under the agency's "expanded access," or "compassionate use" program. Now, new state laws, built on model legislation from the Goldwater Institute in Arizona, will potentially allow doctors and patients to make their own informed decisions on treatments that have cleared the safety phase of FDA testing." Last year, in a move that was seen by some as a response to "Right to Try" laws, the 21st Century Cures Act, a landmark piece of legislation focused on medical innovation and medical research, was signed into law by President Obama. This Act provides the FDA with the flexibility to accelerate how it evaluates regenerative medicine treatments, such as stem cell therapies, while maintaining its high standards of safety and efficacy. "We're on the cusp of a major change on how patients can access stem cell therapy," said Alexander. "Today, new treatments and advances in research are giving new hope to people affected by a wide range of autoimmune and degenerative illnesses," said Alexander. "StemGenex Medical Group is proud to offer the highest quality of care and to potentially help those with unmet clinical needs improve their quality of life." StemGenex Medical Group is committed to helping people achieve optimum health and better quality of life through the healing benefits of their own stem cells. StemGenex provides stem cell therapy options for individuals suffering with inflammatory and degenerative illnesses.  Committed to the science and innovation of stem cell treatment, StemGenex sponsors five clinical outcome studies registered with the National Institutes of Health ("NIH") for Multiple Sclerosis, Parkinson's Disease, Rheumatoid Arthritis, Chronic Obstructive Pulmonary Disease ("COPD") and Osteoarthritis. These have been established to formally document and evaluate the quality of life changes in individuals following adipose-derived stem cell treatment. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/stem-cell-therapy-is-one-step-closer-to-becoming-law-in-texas-300461859.html


News Article | May 26, 2017
Site: www.prweb.com

The American Parkinson Disease Association’s Scientific Advisory Board (SAB) met this week to review more than eighty-nine grant submissions all vying for nearly $1,000,000 in funding that will be awarded to both experienced and emerging young scientists in the Parkinson’s field. The American Parkinson Disease Association (APDA) is focused on advancing scientific research that will support its mission to provide the support, education, and research that will help everyone impacted by Parkinson’s disease live life to the fullest. “APDA is committed to investing in high impact science that can change the course of this disease,” commented Dr. David G. Standaert, Chairman of the SAB. “As we evaluate these proposals we focus on funding researchers who are at the start of their Parkinson’s research career. Our aim is to accelerate research and support translational ideas that have the potential to truly improve the quality of life and make a difference." APDA's SAB is comprised of scientists with a wide array of backgrounds and expertise in all areas relevant to Parkinson's disease (PD) whose research holds promise to discovering new insights etiology and treatment of the disease. Post-Doctoral Fellowships are awarded at $35,000 per year, while Research grants are awarded at $50,000 per year. Additionally, the prestigious Dr. George C. Cotzias Fellowship is a $240,000 grant given over three years to support promising young physicians and researchers who are rising stars working to establish their careers in research, teaching and patient service relevant to the problems, causes, prevention, diagnosis and treatment of PD and related neurological movement disorders. This critical research funding is only possible due to the financial support from APDA’s steadfast supporters and the dedicated work of the SAB who gather on a regular basis to diligently review and recommend funding the most cutting edge projects. The SAB meeting included research presentations from four of APDA’s 2016-2017 grantees who each represent a vast diversity of PD research areas. Post-Doctoral Fellows: Hazem Abdelkarim, PhD, University of Illinois at Chicago: Dr. Abdelkarim is seeking to structurally and biophysically characterize the direct interactions between alpha-synuclein and glycosphingolipids to determine if glycosphingolipids can modulate the association of monomeric alpha-synuclein into either toxic or nontoxic oligomers. Vinita Ganesh Chittoor, PhD, Oregon Health & Science University: Dr. Chittoor is focused on studying the effects of altered dietary amino acids on dopamine neuron degeneration and locomotor impairment associated with mutant G2019S LRRK2, and to assess the role of TOR signaling in the effects of dietary amino acids on G2019S LRRK2-induced phenotype. Findings from either of these studies could potentially lead to drug development that might help slow down PD progression. APDA Research Grantees: Beom-Chan Lee, PhD, University of Houston: The SAB was enthused to see the progress made by Dr. Lee in his work to assess the impacts on long-term rehabilitative training for people with PD who receive in-home balance exercises with assistive guidance via the smartphone-based biofeedback system, called Smarter Balance System (SBS). This work is investigating the effects of improved postural control and how that carries over to confidence in daily activities and less fear of falling. https://www.apdaparkinson.org/research/investigators/hannes-devos-phd/, Kansas University Medical Center: Dr. Devos is comparing the cognitive workload during simple and challenging cognitive tasks between individuals with PD and controls with no neurological condition to understand if those with abnormally high Task Evoked Pupillary Response or TEPR values may be at risk of early cognitive decline. If successful, this TEPR evaluation could alert clinicians very early to cognitive changes that would otherwise go unnoticed. The American Parkinson Disease Association (APDA) proudly invests in the most promising clinicians and scientific projects focused on the discovery of the cause(s) and finding the cure for Parkinson’s disease. APDA is committed to scientific research and has been a funding partner in most major Parkinson’s disease scientific breakthroughs, investing more than $46 million in research since 1961. Many APDA-funded researchers have successfully leveraged pilot data to secure multi-million dollar grants through the National Institute of Health. The announcement of 2017-2018 grant funding will take place in August. About the American Parkinson Disease Association The American Parkinson Disease Association (APDA) is the largest grassroots network dedicated to fighting Parkinson’s disease (PD) and works tirelessly to assist the more than 1 million Americans with PD live life to the fullest in the face of this chronic, neurological disorder. Founded in 1961, APDA has raised and invested more than $170 million to provide outstanding patient services and educational programs, elevate public awareness about the disease, and support research designed to unlock the mysteries of PD and ultimately put an end to this disease.


News Article | May 25, 2017
Site: www.fooddive.com

Consumers are driving food formulations: dietary restrictions, desires, and priorities inspire brands to remove, displace, and add ingredients to align with evolving consumer demands. While the clean label discussion has focused largely on the removal of less-than-desirable ingredients in recent years, adding nutrients, like calcium, is another way that both foodservice and packaged food brands bring value to their customers and differentiate themselves. When fortified with calcium, baked goods can serve as ideal delivery systems for the bone-building nutrient, without any negative impact on texture or taste. Here are a few of the consumer segments for whom calcium-fortified baked goods hold great appeal: Whether packing lunches or jetting from piano lessons to baseball practice, parents seek convenient ways to deliver key nutrients, like calcium, in their families’ foods. Foodservice brands offering on-the-go grub and CPG brands gracing the bread aisle each have an opportunity to deliver good and excellent levels of calcium in their bakery items. Subway, for instance, has long incorporated calcium into its bread, delivering a glass-of-milk level of calcium in each 6-inch sub roll, and Sara Lee® Soft & Smooth® White made with Whole Grain Bread delivers an excellent level of calcium—25% daily value—in just two slices. Even hot dog, bratwurst, and hamburger buns can provide a good source of calcium. While dairy has a long-held reputation for delivering daily calcium requirements, increasing awareness of allergens, growing intolerances, and voluntary avoidance leave people seeking other sources of calcium. According to the National Institute of Health, approximately “30 million adults have some degree of lactose intolerance by age 20.” Incorporating calcium in non-dairy formats, like these calcium-fortified tortillas, provides a friendly delivery system for those with dairy-free or reduced dairy diets. Per the National Osteoporosis Foundation, “when we don’t get enough calcium for our body’s needs, it is taken from our bones.” And while seniors are often recognized as an audience seeking bone-health benefits, athletes, parents, and women are also increasingly aware of the importance of calcium. When fortified with calcium, baked goods, including breads, bagels, and English muffins, can serve as ideal delivery systems for the bone-building nutrient, with the capacity to incorporate calcium without any negative impact to the texture or taste. As with any value-adding attribute, effectively communicating the benefit is a critical component to driving consumer awareness—and demand. Incorporating claims on packaging and in promotions is key in communicating calcium levels and benefits to consumers.

Loading National Institute of Health collaborators
Loading National Institute of Health collaborators